Meiji Seika Pharma has announced the establishment of a local subsidiary, Taiwan Meiji Pharma Co., Ltd.

This subsidiary will focus on pharmaceutical sales and other related activities in Taiwan and is scheduled to commence operations in February 2025.

Meiji Seika Pharma aims to become ‘a company in Asia in the field of infectious diseases’ as part of the ‘Meiji Group 2026 Vision’ targeting the year 2026. By establishing Taiwan Meiji Pharma Co., Ltd. in Taiwan, the fifth largest pharmaceutical market in Asia, we aim to build a business foundation and achieve further growth by supplying products.

Taiwan Meiji Pharma Co., Ltd. plans to launch ‘REZUROCK’ (product name in Japan, generic name: belumosudil mesylate), a selective ROCK2 inhibitor for the treatment of chronic graft-versus-host disease (Chronic GVHD), which is currently under application for regulatory approval with the Taiwan Food and Drug Administration (TFDA).

Chronic GVHD is a disease that occurs following hematopoietic stem cell transplantation performed for the treatment of leukemia.